Johnson & Johnson’s DePuy Synthes unit has entered a definitive agreement with JointPoint, Inc. to acquire its JointPoint Navigation Software.
DePuy Synthes to Acquire Assets of JointPoint, Inc.
1 min read Premium comments
Secondary#depuysynthes#anteriorApproach
Headquartered in Warsaw, Indiana, DePuy Synthes produces one of the most extensive orthopedic technology portfolios worldwide. These products include implants, instruments, imaging, navigation and other systems and services to support joint reconstruction, craniomaxillofacial, trauma and spinal surgery as well as sports medicine.
Clearwater, Florida based JointPoint, Inc. develops and markets medical technology for digital templating and case planning, non-invasive computer navigation and intra-operative feedback. Its technologies are designed to be surgeon-friendly. The company created JointPoint™, “a hip navigation system for intraoperative analysis and digital templating.” JointPoint Navigation Software was developed to promote improved surgical outcomes for hip replacement patients.
DePuy Synthes has had an exclusive agreement to market the JointPoint platform in the U.S. since July 2017. Under the terms of the recently announced agreement, JointPoint’s proprietary software platform will become a component of DePuy’s Anterior Approach solution called ANTERIOR ADVANTAGE.
ANTERIOR ADVANTAGE will synthesize DePuy Synthes implants and instrumentation technologies with JointPoint surgical navigation programs, which are designed to increase surgical accuracy and reproducibility. The ANTERIOR ADVANTAGE solution also contains the KINCISE Surgical Automated System (which automates and improves the precision of key steps during hip replacement surgery) and the ACTIS Total Hip System. Both the KINCISE System and ACTIS System can also be used in traditional posterior hip replacement approaches.
Aaron Villaruz, vice president and global platform leader, hips, DePuy Synthes stated, “JointPoint ties into our strategy to transform hip replacement and is specifically designed for use with the Anterior Approach, a tissue-sparing surgical technique which surgeons are increasingly utilizing and where we have long had an industry-leading presence.”
Noah Wollowick, president and co-founder of JointPoint said, “We are excited to solidify this co-marketing agreement with DePuy Synthes, a worldwide leader in orthopaedics, to gain better access to surgeons across the country that want to use our innovative technology.”
The financial terms have not been disclosed. The transaction is subject to customary closing conditions.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.